Prognosis Relevance of Serum Cytokines in Pancreatic Cancer

被引：21

作者：

Torres, Carolina ^{[1
]}

Linares, Ana ^{[1
]}

Jose Alejandre, Maria ^{[1
]}

Palomino-Morales, Rogelio J. ^{[1
]}

Caba, Octavio ^{[2
]}

Prados, Jose ^{[3
]}

Aranega, Antonia ^{[3
]}

Delgado, Juan R. ^{[4
]}

Irigoyen, Antonio ^{[4
]}

Martinez-Galan, Joaquina ^{[4
]}

Ortuno, Francisco M. ^{[5
]}

Rojas, Ignacio ^{[5
]}

Perales, Sonia ^{[1
]}

机构：

[1] Univ Granada, Dept Biochem & Mol Biol 1, E-18071 Granada, Spain

[2] Univ Jaen, Dept Hlth Sci, Jaen 23071, Spain

[3] Univ Granada, Dept Human Anat & Embryol, Granada 18012, Spain

[4] Virgen de las Nieves Hosp, Oncol Serv, Granada 18014, Spain

[5] Univ Granada, Dept Comp Architecture & Comp Technol CITIC UGR, E-18071 Granada, Spain

来源：

BIOMED RESEARCH INTERNATIONAL | 2015年 / 2015卷

关键词：

ENDOTHELIAL GROWTH FACTOR/PROKINETICIN-1; EG-VEGF; DUCTAL ADENOCARCINOMA; EXPRESSION; BIOMARKERS; LAMBDA; CELLS; IDENTIFICATION; SURVIVAL; MARKERS;

D O I：

10.1155/2015/518284

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although gemcitabine is the standard used chemotherapy for this disease, clinical outcomes do not reflect significant improvements, not even when combined with adjuvant treatments. There is an urgent need for prognosis markers to be found. The aim of this study was to analyze the potential value of serum cytokines to find a profile that can predict the clinical outcome in patients with pancreatic cancer and to establish a practical prognosis index that significantly predicts patients' outcomes. We have conducted an extensive analysis of serum prognosis biomarkers using an antibody array comprising 507 human cytokines. Overall survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox's proportional hazard models were used to analyze prognosis factors. To determine the extent that survival could be predicted based on this index, we used the leave-one-out cross-validation model. The multivariate model showed a better performance and it could represent a novel panel of serum cytokines that correlates to poor prognosis in pancreatic cancer. B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer and these cytokines could represent novel therapeutic targets for this disease.

引用

页数：12

共 63 条

[1] Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer [J].

Anjomshoaa, A. ;

Lin, Y-H ;

Black, M. A. ;

McCall, J. L. ;

Humar, B. ;

Song, S. ;

Fukuzawa, R. ;

Yoon, H. -S ;

Holzmann, B. ;

Friederichs, J. ;

Van Rij, A. ;

Thompson-Fawcett, M. ;

Reeve, A. E. .

BRITISH JOURNAL OF CANCER, 2008, 99 (06) :966-973

[2] Desmoplastic reaction in pancreatic cancer - Role of pancreatic stellate cells [J].

Apte, MV ;

Park, S ;

Phillips, PA ;

Santucci, N ;

Goldstein, D ;

Kumar, RK ;

Ramm, GA ;

Buchler, M ;

Friess, H ;

McCarroll, JA ;

Keogh, G ;

Merrett, N ;

Pirola, R ;

Wilson, JS .

PANCREAS, 2004, 29 (03) :179-187

[3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[4]

Balu S, 2012, ROM J MORPHOL EMBRYO, V53, P479

[5] The Dual Role of Thymidine Phosphorylase in Cancer Development and Chemotherapy [J].

Bronckaers, Annelies ;

Gago, Federico ;

Balzarini, Jan ;

Liekens, Sandra .

MEDICINAL RESEARCH REVIEWS, 2009, 29 (06) :903-953

[6] EG-VEGF: a key endocrine factor in placental development [J].

Brouillet, Sophie ;

Hoffmann, Pascale ;

Feige, Jean-Jacques ;

Alfaidy, Nadia .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2012, 23 (10) :501-508

[7] TUMOR IMMUNOGENICITY DETERMINES THE EFFECT OF B7 COSTIMULATION ON T-CELL-MEDIATED TUMOR-IMMUNITY [J].

CHEN, LP ;

MCGOWAN, P ;

ASHE, S ;

JOHNSTON, J ;

LI, YW ;

HELLSTROM, I ;

HELLSTROM, KE .

JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :523-532

[8] Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib [J].

Clark, Gary M. .

MOLECULAR ONCOLOGY, 2008, 1 (04) :406-412

[9] New biomarkers and targets in pancreatic cancer and their application to treatment [J].

Costello, Eithne ;

Greenhalf, William ;

Neoptolemos, John P. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (08) :435-444

[10]

COX DR, 1972, J R STAT SOC B, V34, P187

← 1 2 3 4 5 6 7 →